share_log

Atara Biotherapeutics Analyst Ratings

Atara Biotherapeutics Analyst Ratings

阿塔拉生物治療分析師評級
Benzinga ·  2023/09/26 18:34
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/26/2023 1617.79% HC Wainwright & Co. → $28 Reiterates Buy → Buy
08/21/2023 -14.11% Citigroup $2 → $1.4 Maintains Sell
08/09/2023 1433.74% EF Hutton → $25 Reiterates Buy → Buy
06/14/2023 1617.79% HC Wainwright & Co. $27 → $28 Maintains Buy
05/09/2023 1126.99% Canaccord Genuity $50 → $20 Maintains Buy
02/09/2023 1433.74% EF Hutton → $25 Reiterates → Buy
02/09/2023 1556.44% HC Wainwright & Co. $29 → $27 Maintains Buy
02/07/2023 1801.84% Mizuho → $31 Reiterates → Buy
01/05/2023 1433.74% EF Hutton → $25 Initiates Coverage On → Buy
08/16/2022 1801.84% Mizuho $39 → $31 Maintains Buy
08/09/2022 84.05% Goldman Sachs $4 → $3 Maintains Sell
07/20/2022 84.05% Citigroup → $3 Downgrades Neutral → Sell
07/13/2022 513.5% JP Morgan → $10 Downgrades Overweight → Neutral
07/13/2022 206.75% Stifel $16 → $5 Downgrades Buy → Hold
05/24/2022 145.4% Goldman Sachs $5 → $4 Maintains Sell
05/23/2022 1679.14% HC Wainwright & Co. $31 → $29 Maintains Buy
05/10/2022 390.8% Citigroup $23 → $8 Downgrades Buy → Neutral
03/28/2022 1249.69% JP Morgan $27 → $22 Maintains Overweight
01/03/2022 1556.44% JP Morgan $26 → $27 Maintains Overweight
05/13/2021 1679.14% JP Morgan $23 → $29 Upgrades Neutral → Overweight
05/05/2021 1801.84% HC Wainwright & Co. $32 → $31 Maintains Buy
12/08/2020 1801.84% HC Wainwright & Co. $28 → $31 Maintains Buy
11/10/2020 1617.79% HC Wainwright & Co. $26 → $28 Maintains Buy
09/15/2020 4685.28% Canaccord Genuity $70 → $78 Maintains Buy
08/06/2020 1617.79% Stifel $30 → $28 Maintains Buy
08/06/2020 1495.09% HC Wainwright & Co. $25 → $26 Maintains Buy
06/30/2020 Evercore ISI Group Initiates Coverage On → Outperform
06/15/2020 1433.74% HC Wainwright & Co. → $25 Initiates Coverage On → Buy
05/12/2020 1311.04% JP Morgan $22 → $23 Maintains Neutral
04/23/2020 Citigroup Upgrades Neutral → Buy
11/08/2019 1249.69% JP Morgan $43 → $22 Downgrades Overweight → Neutral
09/27/2019 452.15% Goldman Sachs $14 → $9 Downgrades Neutral → Sell
09/16/2019 820.25% Jefferies $32 → $15 Downgrades Buy → Hold
06/04/2019 Citigroup Upgrades Sell → Neutral
05/30/2019 1740.49% Roth Capital → $30 Initiates Coverage On → Buy
05/23/2019 2415.34% Stifel → $41 Initiates Coverage On → Buy
01/23/2019 3703.68% Mizuho → $62 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
09/26/2023 1617.79% HC Wainwright公司 →$28 重申 購買→購買
2023年08月21日 -14.11% 花旗集團 $2→$1.4 維護
08/09/2023 1433.74% EF Hutton →$25 重申 購買→購買
2023/06/14 1617.79% HC Wainwright公司 $27→$28 維護
05/09/2023 1126.99% 卡納科特·格納奇 $50→$20 維護
02/09/2023 1433.74% EF Hutton →$25 重申 →購買
02/09/2023 1556.44% HC Wainwright公司 $29→$27 維護
02/07/2023 1801.84% 瑞穗 →$31 重申 →購買
01/05/2023 1433.74% EF Hutton →$25 開始承保 →購買
08/16/2022 1801.84% 瑞穗 $39→$31 維護
08/09/2022 84.05% 高盛 $4→$3 維護
07/20/2022 84.05% 花旗集團 →$3 評級下調 中性→銷售
07/13/2022 513.5% 摩根大通 →$10 評級下調 超重→中性
07/13/2022 206.75% Stifel $16→$5 評級下調 購買→Hold
2022年05月24日 145.4% 高盛 $5→$4 維護
2022年05月23日 1679.14% HC Wainwright公司 $31→$29 維護
2022年05月10日 390.8% 花旗集團 $23→$8 評級下調 購買→中性
03/28/2022 1249.69% 摩根大通 $27→$22 維護 超重
01/03/2022 1556.44% 摩根大通 $26→$27 維護 超重
2021/05/13 1679.14% 摩根大通 $23→$29 升級 中性→超重
05/05/2021 1801.84% HC Wainwright公司 $32→$31 維護
12/08/2020 1801.84% HC Wainwright公司 $28→$31 維護
11/10/2020 1617.79% HC Wainwright公司 $26→$28 維護
2020/09/15 4685.28% 卡納科特·格納奇 $70→$78 維護
08/06/2020 1617.79% Stifel $30→$28 維護
08/06/2020 1495.09% HC Wainwright公司 $25→$26 維護
06/30/2020 - Evercore ISI集團 開始承保 →跑贏大盤
2020/06/15 1433.74% HC Wainwright公司 →$25 開始承保 →購買
2020/05/12 1311.04% 摩根大通 $22→$23 維護 中性
04/23/2020 - 花旗集團 升級 中性→購買
2019年8月11日 1249.69% 摩根大通 $43→$22 評級下調 超重→中性
2019年09月27日 452.15% 高盛 $14→$9 評級下調 中性→銷售
2019/09/16 820.25% 傑富瑞 $32→$15 評級下調 購買→Hold
2019年04月06日 - 花旗集團 升級 賣出→中性
2019年05月30日 1740.49% 羅斯資本 →$30 開始承保 →購買
2019年05月23日 2415.34% Stifel →$41 開始承保 →購買
2019年01月23日 3703.68% 瑞穗 →$62 開始承保 →購買

What is the target price for Atara Biotherapeutics (ATRA)?

Atara BioTreateutics(ATRA)的目標價格是多少?

The latest price target for Atara Biotherapeutics (NASDAQ: ATRA) was reported by HC Wainwright & Co. on September 26, 2023. The analyst firm set a price target for $28.00 expecting ATRA to rise to within 12 months (a possible 1617.79% upside). 9 analyst firms have reported ratings in the last year.

阿塔拉生物療法公司(納斯達克:ATRA)的最新目標價是由HC Wainwright&Co.於2023年9月26日報道的。這家分析公司將目標價定為28美元,預計ATRA將在12個月內上漲(可能上漲1617.79)。去年有9家分析公司公佈了評級。

What is the most recent analyst rating for Atara Biotherapeutics (ATRA)?

Atara BioTreateutics(ATRA)的最新分析師評級是什麼?

The latest analyst rating for Atara Biotherapeutics (NASDAQ: ATRA) was provided by HC Wainwright & Co., and Atara Biotherapeutics reiterated their buy rating.

Atara BioTreatetics(納斯達克代碼:ATRA)的最新分析師評級由HC Wainwright&Co.提供,Atara BioTreateutics重申其買入評級。

When is the next analyst rating going to be posted or updated for Atara Biotherapeutics (ATRA)?

Atara BioTreateutics(ATRA)的下一次分析師評級將於何時發佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atara Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atara Biotherapeutics was filed on September 26, 2023 so you should expect the next rating to be made available sometime around September 26, 2024.

分析師在進行了廣泛的研究後得出了股票評級,其中包括查閱公共財務報表,與Atara BioTreateutics的高管和客戶交談,以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。Atara BioTreatetics的上一次評級是在2023年9月26日提交的,所以你應該預計下一次評級將在2024年9月26日左右的某個時候提供。

Is the Analyst Rating Atara Biotherapeutics (ATRA) correct?

分析師對Atara BioTreateutics(ATRA)的評級正確嗎?

While ratings are subjective and will change, the latest Atara Biotherapeutics (ATRA) rating was a reiterated with a price target of $0.00 to $28.00. The current price Atara Biotherapeutics (ATRA) is trading at is $1.63, which is within the analyst's predicted range.

雖然評級是主觀的,並將發生變化,但最新的Atara BioTreateutics(ATRA)評級被重申,目標價在0.00美元至28.00美元之間。目前Atara BioTreateutics(ATRA)的交易價格為1.63美元,在分析師的預測範圍內。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論